Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2014  |  Volume : 10  |  Issue : 8  |  Page : 292-295

The relationship between P16 gene promoter methylation and gastric cancer: A meta-analysis based on Chinese patients

1 Department of Medical Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022; First Department of Surgical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China
2 Department of General Surgery, The Central Hospital of Lishui City, Lishui, Zhejiang 323000, China
3 Department of Medical Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China

Correspondence Address:
Guoping Sun
Department of Medical Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-1482.151535

Rights and Permissions

Objective: To evaluate the P16 gene promoter methylation rate in gastric cancer tissue and healthy controls. And further assess the clinical value of P16 gene promoter methylation as a biomarker for gastric cancer diagnosis. Materials and Methods: Four databases, Medline, VIP, CNKI, WANFANG were searched to find the diagnostic trials about P16 gene promoter methylation in gastric cancer and healthy control. The pooled sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (-LR) and the receiver operating characteristic curve (ROC) were calculated by Meta-DiSc1.4 (http://www.hrc.es/investigacion/metadisc.html) software. Results: Nine studies involving 487 gastric cancer patients and 271 healthy controls were included in this meta-analysis. The median methylation rate for gastric cancer group was 43.3% with its range of 28.3-64.4%. And the median methylation rate for healthy control group was 0.0% with its range of 0.0-13.3%. The methylation rate in gastric cancer was statistical higher than in the healthy control (P < 0.05). The pooled sensitivity, specificity, +LR, -LR and the area under the ROC curve were 0.44 (95% confidence interval [CI]: 0.40-0.49), 0.97 (95% CI: 0.95-0.99), 13.11 (95% CI: 4.02-42.63), 0.58 (95% CI: 0.49-0.70), 23.62 (95% CI: 6.90-80.90) and 0.44, respectively. Conclusion: Our meta-analysis indicates that P16 gene promoter methylation array is a useful method for diagnosis of gastric cancer with relatively low sensitivity and very high specificity.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded123    
    Comments [Add]    

Recommend this journal